Patterns of Peripheral Blood B-Cell Subtypes Are Associated With Treatment Response in Patients Treated With Immune Checkpoint Inhibitors: A Prospective Longitudinal Pan-Cancer Study.
B cells
cancer
immune checkpoint inhibitor therapy
lymphocytes
response
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
20
12
2021
accepted:
10
03
2022
entrez:
18
4
2022
pubmed:
19
4
2022
medline:
20
4
2022
Statut:
epublish
Résumé
Immune checkpoint inhibitors (ICIs) have revolutionized systemic anti-tumor treatments across different types of cancer. Nevertheless, predictive biomarkers regarding treatment response are not routinely established yet. Apart from T-lymphocytes, the humoral immunity of B-lymphocytes is studied to a substantially lesser extent in the respective setting. Thus, the aim of this study was to evaluate peripheral blood B-cell subtypes as potential predictors of ICI treatment response. Thirty-nine cancer patients receiving ICI therapy were included into this prospective single-center cohort study. All had a first blood draw at the date before treatment initiation and a second at the time of first response evaluation (after 8-12 weeks). Seven different B-cell subtypes were quantified by fluorescence-activated cell sorting (FACS). Disease control- (DCR) and objective response rate (ORR) were co-primary study endpoints. Overall, DCR was 48.7% and ORR was 25.6%, respectively. At baseline, there was no significant association of any B-cell subtype with neither DCR nor ORR. At the first response evaluation, an increase in the frequency of CD21 In this study, certain B-cell subpopulations were associated with ICI treatment response in various human cancer types.
Sections du résumé
Background
Immune checkpoint inhibitors (ICIs) have revolutionized systemic anti-tumor treatments across different types of cancer. Nevertheless, predictive biomarkers regarding treatment response are not routinely established yet. Apart from T-lymphocytes, the humoral immunity of B-lymphocytes is studied to a substantially lesser extent in the respective setting. Thus, the aim of this study was to evaluate peripheral blood B-cell subtypes as potential predictors of ICI treatment response.
Methods
Thirty-nine cancer patients receiving ICI therapy were included into this prospective single-center cohort study. All had a first blood draw at the date before treatment initiation and a second at the time of first response evaluation (after 8-12 weeks). Seven different B-cell subtypes were quantified by fluorescence-activated cell sorting (FACS). Disease control- (DCR) and objective response rate (ORR) were co-primary study endpoints.
Results
Overall, DCR was 48.7% and ORR was 25.6%, respectively. At baseline, there was no significant association of any B-cell subtype with neither DCR nor ORR. At the first response evaluation, an increase in the frequency of CD21
Conclusion
In this study, certain B-cell subpopulations were associated with ICI treatment response in various human cancer types.
Identifiants
pubmed: 35432362
doi: 10.3389/fimmu.2022.840207
pmc: PMC9010871
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
840207Subventions
Organisme : Austrian Science Fund FWF
ID : W 1226
Pays : Austria
Informations de copyright
Copyright © 2022 Barth, Stanzer, Spiegelberg, Bauernhofer, Absenger, Szkandera, Gerger, Smolle, Hutterer, Ahyai, Madl, Posch, Riedl, Klec, Jost, Kargl, Stradner and Pichler.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Nat Rev Immunol. 2020 May;20(5):294-307
pubmed: 31988391
Blood. 2008 Jan 1;111(1):77-85
pubmed: 17898316
Immunity. 2018 Mar 20;48(3):434-452
pubmed: 29562194
Immunity. 2010 Jan 29;32(1):129-40
pubmed: 20079667
FEBS J. 2017 Jul;284(13):1952-1966
pubmed: 28132417
Nat Rev Cancer. 2019 Mar;19(3):133-150
pubmed: 30755690
Cell Mol Immunol. 2021 Apr;18(4):842-859
pubmed: 33139907
Nat Immunol. 2009 Dec;10(12):1292-9
pubmed: 19855380
ESMO Open. 2021 Aug;6(4):100198
pubmed: 34175674
Nat Commun. 2019 Sep 13;10(1):4186
pubmed: 31519915
Blood. 2011 May 19;117(20):5425-37
pubmed: 21421840
Exp Mol Med. 2018 Dec 13;50(12):1-11
pubmed: 30546008
Front Immunol. 2020 Oct 09;11:563653
pubmed: 33162976
Mol Aspects Med. 2019 Dec;70:117-126
pubmed: 31582259
Nature. 2020 Jan;577(7791):549-555
pubmed: 31942075
J Immunol. 2021 Apr 1;206(7):1478-1482
pubmed: 33558375
Blood. 2010 Jun 17;115(24):5026-36
pubmed: 20231422
Cell Mol Immunol. 2019 Jan;16(1):6-18
pubmed: 29628498
Proc Natl Acad Sci U S A. 2009 Aug 11;106(32):13451-6
pubmed: 19666505
Oral Oncol. 2019 Dec;99:104460
pubmed: 31683169
Br J Cancer. 2018 Jan;118(1):9-16
pubmed: 29319049
Nat Rev Clin Oncol. 2019 Jun;16(6):356-371
pubmed: 30705439
J Immunol. 2012 Oct 15;189(8):3925-35
pubmed: 22972930
Front Immunol. 2021 Nov 04;12:756042
pubmed: 34804042
Nat Med. 2018 Nov;24(11):1649-1654
pubmed: 30297909
Front Immunol. 2021 Dec 07;12:803742
pubmed: 34950155
Scand J Immunol. 2015 Sep;82(3):254-61
pubmed: 26119182
Nat Rev Immunol. 2020 Nov;20(11):651-668
pubmed: 32433532
Am J Respir Crit Care Med. 2014 Apr 1;189(7):832-44
pubmed: 24484236
Front Cell Dev Biol. 2021 Jun 07;9:678127
pubmed: 34164398
Blood. 2011 Sep 22;118(12):3440-1; author reply 3442
pubmed: 21940829
Cells. 2019 May 13;8(5):
pubmed: 31086070